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Background: The purpose of this research was to fully explore the impact of endpoint type (primary vs.
nonprimary) on decisions related to patient-reported outcome (PRO) labeling claims supported by PRO measures
and to determine if nonprimary PRO endpoints are being fully optimized.
This review examines the use of PROs as both primary and nonprimary endpoints in support of demonstration of
treatment benefit of new molecular entities (NMEs) and biologic license applications (BLAs) in the United States in
the years 2000 to 2012.
Methods: All NMEs and BLAs approved by the Food and Drug Administration (FDA) between January 2000 and
June 2012 were identified using the FDA Drug Approval Reports Web page. Generic products granted tentative
approvals were excluded. For all identified products, medical review sections from publicly available drug approval
packages were reviewed to identify PRO endpoint status. Product labels (indication, clinical trials sections) were
reviewed to determine the number and type of PRO claim.
Results: A total of 308 NMEs/BLAs were identified. Of these, 70 NMEs/BLAs (23%) were granted PRO claims. The
majority of product claims were for disease- or condition-specific signs and symptoms. Of the 70 products with
PRO claims, a PRO was a primary endpoint for the vast majority (57 [81%]). A total of 19 of the 70 products were
granted a PRO claim based on a nonprimary endpoint. While nonprimary endpoints were used most often to
support claims of improved signs or symptoms, nonprimary endpoints were much more likely to support claims of
higher order impacts.
Conclusions: Successful PRO labeling claims are typically based on primary endpoints assessing signs and
symptoms. Based on this research, studies with PROs as primary endpoints are far more likely to facilitate positive
regulatory review and acceptance of PROs in support of labeling claims. Although inclusion of PROs as nonprimary
endpoints in clinical trials has its challenges, recent PRO labels granted by the FDA show that they can indeed be
candidates for PRO labeling claims as long as they are supported by evidence.
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Patient-reported outcome (PRO) is an umbrella term
used to describe data collected directly from the patient
without interpretation by clinicians or others [1-3]. PRO
data are collected using standardized questionnaires,
diaries, or event logs that are designed to measure an
explicit concept (construct), such as signs and symp-
toms of disease, functioning (activity limitations), health
status/health-related quality of life (HRQOL), and* Correspondence: ari.gnanasakthy@novartis.com
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distribution, and reproduction in any mediumtreatment satisfaction. PROs are frequently included in
registration clinical trials for multiple purposes, inclu-
ding support of product approvals and labeling claims
of treatment benefit, support of primary endpoints, and
to provide a basis for publication and communication
strategies. Also, increased competition in a global mar-
ket requires pharmaceutical companies to seek methods
to differentiate their products from those of competi-
tors. One way of achieving this goal is to generate value
propositions that extend beyond the traditional safety
and clinical efficacy messages and allow competition on
something other than price alone. PRO measuresentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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treatment benefit.
Primary endpoints are intended to address the most
important research being addressed by a trial. In the ab-
sence of objective clinical endpoints to support efficacy,
PRO measures may be used as primary endpoints. PROs
used as primary endpoints are typically those that dir-
ectly assess drug efficacy by measuring disease-defining
signs and symptoms. Examples of indications for which
PROs consistently serve as primary endpoints include
painful conditions, such as migraine and neuropathic
pain, as well as functional gastrointestinal disorders.
PROs may also be used in clinical trials as nonprimary
endpoints to provide support for primary endpoints.
For example, among conditions for which there are well-
accepted clinician-reported primary endpoints, such as
depression and other psychiatric indications, PRO mea-
sures addressing patients’ perceptions of their symptom
severity, such as the Beck Depression Inventory or the
Zung Self-Rating Depression Scale, are often used as key
secondary endpoints. In addition to signs and symptoms,
nonprimary PRO endpoints often assess higher order
constructs such as functional status and HRQOL. In
many instances, PROs are included in confirmatory trials
at the request of regulatory bodies, such as the FDA and
the European Medicines Agency (EMA) [4] or to secure
reimbursement [5].
Sponsors commonly include nonprimary PRO end-
points to demonstrate value propositions of new me-
dicines to stakeholders other than regulatory agencies
[6,7]. For example, demonstration of improvement in
work productivity is important in the treatment of
rheumatoid arthritis [8]. Nonprimary PRO endpoints
also may be included in clinical trials to satisfy health
technology assessment (HTA) requirements. For ex-
ample, the National Institute for Health and Clinical
Excellence (NICE) has recommended patient scores in
Adult Growth Hormone Deficiency scale (QoL-AGHDA)
as one of the three criteria for judging patient suitability
for treatment with recombinant human growth hormone
[6], and the EQ-5D is included in most confirmatory
clinical trials to demonstrate the economic value propo-
sitions of new medicines. Risks of not including a PRO
include inaccurate reporting or understanding of patient
symptoms and symptom severity related to treatment, im-
portant prognostic information, and insight into patient
decision making and adherence to therapy [9].
A recent review of PRO labels between 2006 and 2010
found that almost half (45%) of all drug approval pack-
age submissions included PROs and that a vast majority
of PRO labeling claims (71%) were granted for evidence
based on the primary endpoint [10]. The purpose of this
research is to fully explore the impact of endpoint type
(primary vs. nonprimary) on resultant labeling claimsover a 12 ½ -year period supported by PRO measures
and determine if nonprimary endpoints are being fully
optimized. This review will further contribute to conti-
nued analyses of the role of PROs in clinical trials and
provide a broader perspective, including an examination
of the nonprimary endpoints pre- and postrelease of the
FDA PRO guidance [3].
Methods
The methods for the data collection component for this
research are fully described in a previous publication [10]
and are similar to those published by Willke and col-
leagues [11]. Briefly, all new molecular entities (NMEs)
and biological license applications (BLAs) for new pre-
scription drugs approved in the United States (US) from
January 2000 through June 2012 were reviewed. Products
were excluded if they contained substances previously
marketed with a different brand name or set of indica-
tions, in a different dosage form or strength, or as a com-
bination product of previously marketed entities.
Once products were identified, drug approval packages
(DAP) and approved product labels were extracted by a
single researcher and reviewed by all authors. As avail-
able, information was retrieved from the medical review,
summary review, cross-discipline team leader review,
and other review sections from the DAP, as well as the
indication and clinical studies section of the approved
product label. The DAPs were located on the FDA Web
site, Drugs@FDA [12]. In most cases, the label was
found on the FDA Web site under approval history for
the drug at time of approval. In the event the approved
label was unavailable for the specified timeframe, the
current label was used. Relevant information was scruti-
nized for each product to determine the indication, use
of PRO, and PRO claim language. Statistical analysis
consisted of simple frequencies and cross-tabulations of
measured characteristics. Calculations were performed
using Microsoft Excel 2007.
Results
A total of 308 NMEs/BLAs were identified between the
years 2000 and 2012. Of these, 70 (23%) NMEs/BLAs
were granted a total of 83 PRO claims. A PRO was in-
cluded as a primary endpoint for 57 of the 70 products
(81%). The majority of product claims granted were for
disease- or condition-specific signs and symptoms. Fewer
claims included higher order measures such as function-
ing, HRQOL, or patient global ratings. Table 1 depicts
the products that were granted PRO labeling claims by
type of claim.
Additionally, 19 products received a total of 29 PRO
labeling claims using a PRO that was a nonprimary end-
point. These claim types included signs and symptoms
(n = 19), functioning (n = 2), HRQOL (n = 3), and other
Table 1 PRO labeling claims by type of claim (2000-2012)
Type of claim
(N = 83)
Products with PRO claim (N = 70)
Number of claims Percentage of claims
Signs and symptoms 59 84
Functioning 13 19
HRQOL 3 4
Patient global rating 3 4
Other 5 7
HRQOL, health-related quality of life; PRO, patient-reported outcome.
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satisfaction, and 1 for belly appearance distress). Import-
antly, of these, the vast majority were claims based on
signs or symptoms, as compared with higher order
claims, and were supportive of (but not redundant with)
the primary endpoint. However, nonprimary endpoints
were more likely to represent claims based on concepts
other than signs and symptoms as compared with pri-
mary PRO endpoints (Figure 1).
Protonix received a labeling claim of “complete relief
of daytime and nighttime heartburn and the absence of
regurgitation” based on the patient daily diary as well as
an indication of “symptomatic relief.” The primary end-
point in the clinical studies was resolution of macroscopic
esophageal lesion. Foradil, Nexium, and Frova followed
similar patterns, where the nonprimary PRO endpoint
provided key support to a clinical, objective endpoint.
Foradil, indicated for “maintenance treatment of asthma
and in the prevention of bronchospasm in adults and
children” is notable, because the labeling claim specifically
denotes, “Foradil demonstrated improvement in many
secondary efficacy endpoints, including combined andFigure 1 PRO claim based on endpoint status (2000-2012).nocturnal asthma symptom scores, fewer nighttime awak-
enings and fewer nights in which patients used rescue
medication.” Emend (aprepitant) was granted a higher
order claim of “A higher proportion of patients receiving
Emend reported minimal or no impact of nausea and
vomiting on daily life” based on the Functional Living
Index-Emesis (FLIE), whereas the primary endpoint was
“complete response” or no emesis. Soliris and Letairis also
received higher order claims, though in these instances
they were in support of HRQOL. Table 2 describes the
claim granted and PRO used by product for the 19 prod-
ucts with PRO labeling claims based on nonprimary PRO
endpoints.
Discussion
In the absence of objective clinical endpoints to support
efficacy, PRO measures are often used as primary end-
points. PROs may also offer support to a primary endpoint
as key secondary, secondary, or exploratory endpoints,
which may be either independent of or closely associated
with the primary endpoint. Based on this review, PRO la-
beling claims are more likely to be granted for PROs spe-
cified as primary endpoints in confirmatory clinical trials.
A variety of reasons could explain the limited number of
claims granted based on nonprimary endpoints. The three
most prominent reasons are overlapping concepts, com-
mitment to resource, and logistical complexities.
Overlapping concepts
Primary and nonprimary endpoints may measure the
same or very similar constructs. Clinical trial endpoints
are intended to characterize a clinical outcome of inter-
est. In an oncology clinical trial, an objective endpoint is
Table 2 Nonprimary endpoints used in medical labeling (2000-2012)
Product Date of approval Indication PRO measures included
Protonix February 2, 2000 Short-term treatment in the healing and symptomatic relief of erosive esophagitis Daily diary: frequency and severity of acid regurgitation,
dysphagia, and daytime and nighttime symptoms
Frova January 18, 2001 Acute treatment of migraine with or without aura in adults Headache diary with associated symptoms
Foradil February 16, 2001 Maintenance treatment of asthma and prevention of bronchospasm in adults and children
aged 5 years and older
Daily diary: nighttime asthma symptom score, daytime
asthma symptom score, number of inhalations of
rescue medicationAcute prevention of exercise-induced bronchospasm
Nexium February 20, 2001 Short-term treatment in the healing and symptomatic resolution of diagnostically confirmed
erosive esophagitis
Daily symptom diary
Maintenance of symptom resolution and healing of erosive esophagitis
Treatment of heartburn and other symptoms related to GERD
Treatment of patients with H. pylori infection and duodenal ulcer disease
Elidel December 13, 2001 Short-term and intermittent long-term therapy in the treatment of mild to moderate atopic
dermatitis
Unnamed purities assessment
Emend March 27, 2003 Prevention of acute and delayed nausea and vomiting associated with initial and repeat
courses of highly emetogenic cancer chemotherapy
FLIE
Nevanac August 19, 2005 Treatment of pain and inflammation associated with cataract surgery Ocular pain scale
Chantix May 10, 2006 Aid to smoking cessation treatment QSU-Brief
MNWS
SEI
Vyvanse February 23, 2007 Treatment of ADHD CPRS
Soliris March 16, 2007 Treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis FACIT-Fatigue
EORTC QLQ-C30
Letairis June 15, 2007 Treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO class II or
III symptoms to improve exercise capacity and delay clinical worsening
SF-36 Health Survey
Durezol June 23, 2008 Treatment of inflammation and pain associated with ocular surgery VAS – eye pain/discomfort
VAS – photophobia
Ampyra January 22, 2010 Indicated to improve walking in patients with multiple sclerosis MSWS-12
Egrifta November 10, 2010 Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy Distress associated with belly appearance
Arcapta July 1, 2011 Long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in



























Table 2 Nonprimary endpoints used in medical labeling (2000-2012) (Continued)
Firazyr August 25, 2011 Treatment of acute attacks of hereditary angioedema Symptom VAS
Rescue medication
Jakafi November 16, 2011 Treatment of patients with intermediate or high-risk myelofibrosis, including primary
myelofibrosis, postpolycythemia vera myelofibrosis and postessential thrombocythemia
myelofibrosis
MFSAF diary
Kalydeco January 31, 2012 Treatment of cystic fibrosis in patients aged 6 years and older who have a G551D mutation
in the CFTR gene
CFQ-R (symptoms domain)
Asclera March 30, 2010 Treatment of uncomplicated spider veins and uncomplicated reticular veins in the lower
extremity
Patient satisfaction using a verbal rating scale
ADHD, attention deficit hyperactivity disorder; CFQ-R, Cystic fibrosis questionnaire-revised; CFTR, cystic fibrosis transmembrane conductance regulator; COPD, chronic obstructive pulmonary disease; CPRS, Conners’
parent rating scale; EORTC QLQ-C30, European organisation for research and treatment of cancer quality of life questionnaire - core questionnaire; FACIT, Functional assessment of chronic illness therapy; FLIE,
Functional living index-emesis; GERD, gastroesophageal reflux disease; MFSAF, Myelofibrosis Symptom assessment form; MNWS, Minnesota nicotine withdrawal scale; MSWS-12, 12-item multiple sclerosis walking scale;
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In some instances, endpoints may overlap to the point
where no new information is supplied by the nonprimary
endpoint. Examples are use of a pain scale and a patient
diary that measures the same features of pain, multiple
functional scales or an event log and a self-reported ques-
tionnaire in studies of female sexual dysfunction [13].
Commitment to resource
Early stages of product development can be an important
time to develop new PRO measures. However, sponsors
may not commit resources for PRO measures for non-
primary endpoints during the early stages of product
development when the likelihood of changes to target
product profile and the rate of attrition are still high. The
use of inappropriate instruments and the lack of explan-
ation for the choice of PRO measures in clinical trials have
been concerns for many researchers [14-16]. However,
attention to appropriate measures, even for nonprimary
endpoints, may pay dividends. For example, the recent
approval of Myrbetriq for the treatment of overactive
bladder shows that investing in nonprimary PRO end-
points can add value. The nonprimary PROs were not
included in labeling but were still instrumental in the
approval of the product, with an advisory board member
noting, “I wouldn’t have voted on the affirmative if it
wasn’t that there was a signal in the quality of life mea-
sures.” Including generic instruments or instruments
that do not measure the intended concept in the most
appropriate manner in the late stages of product deve-
lopment is unlikely to result in labeling claims.
Logistical complexities
Inclusion of PRO endpoints in multinational clinical tri-
als brings unique challenges [17]. Culturally adapted
PRO instruments, certificates of translation, data collec-
tion devices and training manuals in local languages
need to be in place at the start of a study. Companies
pressed for time may avoid the logistical complexities
related to nonprimary PRO endpoints during the execu-
tion of a multiregional study. Such complexities include
protocol amendments (changes to inclusion and exclusion
criteria for patient characteristics while the study is on-
going) and the need to close study centers in some coun-
tries and open new centers in other countries (resulting in
the need for translations, which cause time delays).
The limited number of US labeling claims based on
nonprimary PRO endpoints may also be due to the fact
that companies include PROs as nonprimary endpoints
in confirmatory clinical trials to satisfy stakeholders
other than the FDA, such as other regulatory bodies,
health authorities, and third-party payers. As such, there
may not have been any attempt to seek US labeling or
meet the requirements in the FDA PRO guidance. Forexample, The Institute for Quality and Efficiency in
Health Care in Germany (IQWIG) seeks data to support
patient-related benefits and characterizes this view as a
type of efficacy [18]. PRO and HRQOL measures may be
used in this manner but must demonstrate that they are
valid for this purpose.Emerging trends
Another distinction worthy of recognition is a product
being approved as first in class versus those entering a
crowded market. First-in-class therapeutics do not need to
rely on differentiation strategies. Sponsors seeking the
fastest path to approval may elect to forego secondary
PRO endpoints in registration trials and instead seek them
in new indications. However, doing so may ultimately be a
disadvantage. Including a PRO for these first-in-class pro-
ducts may satisfy regulatory needs (support the primary or
biomarker) but also meet HTA needs and set the standard
for future competitor products. Companies may be begin-
ning to include PROs as nonprimary endpoints with the
rigor required to secure a labeling claim. For example, in
the recent approval of Jakafi, a first-in-class treatment for
patients with intermediate or high-risk myelofibrosis, a
PRO labeling claim was granted on the basis of evidence
regarding symptoms related to myelofibrosis, a secondary
endpoint in the confirmatory clinical trials [19].
Importantly, on a regulatory level, there may also be a
shift in recognition of the importance of PROs as second-
ary endpoints. A review of Kalydeco, approved in 2011, is
instructive. In the confirmatory clinical trials for Kalydeco,
a treatment for patients with cystic fibrosis, the primary
endpoint was change in percentage predicted FEV1, and
one of the secondary endpoints was symptoms associated
with cystic fibrosis as measured by the Cystic Fibrosis
Questionnaire-Revised (CFQ-R). A PRO label was granted
for “improved symptoms” based on the CFQ-R, despite
reviewer notation in the advisory board minutes that the
measure does not meet the standard for validation and de-
velopment described in the PRO guidance. The reviewer
indicated that it was the compelling nature of the data that
supported the inclusion of the PRO endpoints in the
labeling.Guidance on reporting PRO in RCTs
Efforts to improve reporting in RCTs by CONSORT
(Consolidated Standards of Reporting Trials) include the
reporting of PRO data for trials, including PROs as pri-
mary or secondary measures [20]. Such recommenda-
tions may improve not only the reporting of PRO data
in RCTs but also the planning and execution of PROs so
that the suggested data elements may be reliably
reported. Ultimately, these improvements could result in
an increase in PRO claims granted.
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This review based on 70 PRO labeling claims granted by
the FDA between 2000 and 2012 shows that successful
PRO labeling claims are typically based on primary end-
points assessing signs and symptoms (81.4%). Although
inclusion of PROs as nonprimary endpoints in clinical
trials has its challenges, recent PRO labels granted by
the FDA show that they can indeed be candidates for
PRO labeling claims as long as they can be supported by
evidence. The PRO guidance by the FDA has provided
the industry with a blueprint for obtaining PRO labels
[3]. It is now left to the industry to accept the challenge
and recognize the importance of outcomes that matter
to all stakeholders, including patients.
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